Department of Immunology, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB, R3E 0T5, Canada.
Research Institute in Oncology and Hematology, CancerCare Manitoba, 675 McDermot Ave., Winnipeg, MB, R3E 0V9, Canada.
Leukemia. 2018 Sep;32(9):1958-1969. doi: 10.1038/s41375-018-0012-5. Epub 2018 Jan 31.
The PI 3-kinases (PI3K) are essential mediators of chemokine receptor signaling necessary for migration of chronic lymphocytic leukemia (CLL) cells and their interaction with tissue-resident stromal cells. While the PI3Kδ-specific inhibitor idelalisib shows efficacy in treatment of CLL and other B cell malignancies, the function of PI3Kγ has not been extensively studied in B cells. Here, we assess whether PI3Kγ has non-redundant functions in CLL migration and adhesion to stromal cells. We observed that pharmaceutical PI3Kγ inhibition with CZC24832 significantly impaired CLL cell migration, while dual PI3Kδ/γ inhibitor duvelisib had a greater impact than single isoform-selective inhibitors. Knockdown of PI3Kγ reduced migration of CLL cells and cell lines. Expression of the PI3Kγ subunits increased in CLL cells in response to CD40L/IL-4, whereas BCR cross-linking had no effect. Overexpression of PI3Kγ subunits enhanced cell migration in response to SDF1α/CXCL12, with the strongest effect observed within ZAP70 + CLL samples. Microscopic tracking of cell migration within chemokine gradients revealed that PI3Kγ functions in gradient sensing and impacts cell morphology and F-actin polarization. PI3Kγ inhibition also reduced CLL adhesion to stromal cells to a similar extent as idelalisib. These findings provide the first evidence that PI3Kγ has unique functions in malignant B cells.
PI3-激酶(PI3K)是趋化因子受体信号转导所必需的关键介质,对于慢性淋巴细胞白血病(CLL)细胞的迁移及其与组织驻留基质细胞的相互作用至关重要。虽然 PI3Kδ 特异性抑制剂idelalisib 在治疗 CLL 和其他 B 细胞恶性肿瘤方面显示出疗效,但 PI3Kγ 在 B 细胞中的功能尚未得到广泛研究。在这里,我们评估了 PI3Kγ 在 CLL 迁移和与基质细胞黏附中是否具有非冗余功能。我们观察到,用 CZC24832 进行药物抑制 PI3Kγ 显著损害了 CLL 细胞的迁移,而双重 PI3Kδ/γ 抑制剂 duvelisib 的影响大于单一同工酶选择性抑制剂。PI3Kγ 的敲低减少了 CLL 细胞和细胞系的迁移。CD40L/IL-4 刺激可使 CLL 细胞中 PI3Kγ 亚基的表达增加,而 BCR 交联则没有影响。PI3Kγ 亚基的过表达增强了对 SDF1α/CXCL12 的细胞迁移反应,在 ZAP70+CLL 样本中观察到最强的效果。在趋化因子梯度内对细胞迁移进行显微镜跟踪显示,PI3Kγ 可在梯度感应中发挥作用,并影响细胞形态和 F-肌动蛋白极化。PI3Kγ 抑制也以类似于 idelalisib 的程度减少了 CLL 对基质细胞的黏附。这些发现首次提供了证据表明 PI3Kγ 在恶性 B 细胞中具有独特的功能。